CTIS2024-513270-21-00招募中1 期
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications - C4951012/BHV3000-407
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Pfizer Inc.
- 入组人数
- 559
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Target Population: Minimum 1 year documented history of migraines (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition.3 Per self-report, with confirmation from Investigator / supporting medical record, subjects must have: a. Migraine attacks present for more than 1 year from the Screening Visit b. Age of onset prior to 50 years of age c. Migraine attacks lasting about 4–72 hours, if untreated d. 4 to 14 migraine days, on average, across the 3 months prior to the Screening Visit e. 4 to 14 migraine days during the 28-day Observation Phase f. Subjects must be able to distinguish migraine attacks from tension headaches g. Prior inadequate response, within 10 years of the Screening Visit, to agents across 2-4 categories of recognized, orally-administered migraine-preventive medications where at least one example of prior inadequate response is due to lack of efficacy or prior intolerance (not contraindication), Age and Reproductive Status: a) Subjects =18 years-old b) Subject meets reproductive criteria. Refer to Section 16.6 c) At the Baseline Visit, prior to dispensing investigational study drug, WOCBP must have a negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) before dosing with study drug. For further inclusion criteria, please refer to the Protocol
排除标准
- •Target Disease Exclusion a) History of cluster headaches, basilar migraine (with aura), or hemiplegic migraine b) Current medication overuse headaches c) 15 or more headache days (migraine or non-migraine) per month in any of the 3-months prior to the Screening Visit or during the 28-day Observation Phase d) 7 or more non-migraine headache days per month, on-average, across the 3-months prior to the Screening Visit or during the 28-day Observation Phase e) Inadequate response to agents across > 4 categories of recognized, orally administered, migraine-preventive medications, Medical History and Current Diseases: a) History of gastric or small intestinal surgery or disease or conditions that causes malabsorption b) BMI = 35kg/m2 c) Alcohol or drug abuse within the past 12 months or subjects with any significant substance use disorder within the past 12 months from the date of the Screening Visit d) Current diagnosis of major depressive disorder requiring treatment with an atypical antipsychotic e) Current diagnosis of schizophrenia, bipolar disorder, or borderline personality disorder f) Other major psychiatric disorder that might interfere with the ability to properly report clinical outcomes g) Major depressive disorder or any anxiety disorder which requires more than 1 daily medication for each disorder. h) Major depressive episode within last 12 months prior to the Screening Visit. i) Subjects who meet criteria for C-SSRS Suicidal Ideation Items 4 or 5 within the last 12 months prior to the Screening Visit, OR subjects who endorse any of the 5 C-SSRS Suicidal Behavior Items within the last 10 years prior to the Screening Visit, OR subjects who present a serious risk of suicide j) Active chronic pain syndromes k) Other pain syndromes (including trigeminal neuralgia), dementia, significant neurological disorders other than migraine l) Current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease m) Myocardial infarction, acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), cardiac surgery, stroke or transient ischemic attack within 6 months prior to the Screening Visit n) Uncontrolled hypertension (high blood pressure). o) Any unstable medical conditions (e.g., history of congenital heart disease, arrhythmia, or cancer) p) Positive drug screen for drugs of abuse that in the Investigator's judgment is medically significant, in that it would impact the safety of the subject or the interpretation of the study results., Allergies and Adverse Drug Reactions: History of drug or other allergy which, in the opinion of the investigator, makes the subject unsuitable for participation in the study., Sex and Reproductive Status WOCBP who are unwilling or unable to use required contraception a) Women who are pregnant or breastfeeding b) Women with a positive pregnancy test at Screening Visit, ECG and Laboratory Test Findings - as specified in the protocol., Prohibited Medications and Devices a) Recognized migraine-preventive medication taken within 30 days prior the Screening (with exceptions) b) Non-Narcotic Analgesics or paracetamol taken 15 days per month during the 3 months prior to the Screening Visit c) Any device for migraine prevention or treatment within 3 months prior to the Screening Visit d) Ergotamine taken 10 days per month on a regular basis for 3 months in the year prior to the Screening Visit e) Narcotic, such as opioid or barbiturate taken for 4 days per month during the 3 months prior
研究者
相似试验
招募中
1 期
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan UseMigraine attacks with or without auraMedDRA version: 20.0Level: PTClassification code: 10027599Term: Migraine Class: 100000004852CTIS2024-513269-37-00Pfizer Inc.564
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of ageMedDRA version: 20.0Level: PTClassification code: 10027599Term: Migraine Class: 100000004852MigraineCTIS2024-512382-13-00Pfizer Inc.1,375
招募中
1 期
Randomized study in children and adolescents with migraine: Acute TreatmentCTIS2024-512743-23-00Pfizer Inc.2,100
进行中（未招募）
3 期
CA209-7G8/ONO-4538-110:Phase 3JPRN-jRCT2031210118Hirashima Yoshinori46
进行中（未招募）
不适用
A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIOUSLY TAKEN VARENICLINESmoking CessationMedDRA version: 15.0Level: PTClassification code 10053325Term: Smoking cessation therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-021789-31-DEPfizer Inc.235 East 42nd Street, New York, NY 10017 US490